2022
Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis
Savinkina A, Paltiel A, Ross J, Gonsalves G. Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis. Open Forum Infectious Diseases 2022, 9: ofac637. PMID: 36589482, PMCID: PMC9792084, DOI: 10.1093/ofid/ofac637.Peer-Reviewed Original ResearchCost-effectiveness analysisTrade-offs implicitSevere diseaseDecision analytic modelAllocation decisionsPay thresholdsPolicy strategiesUnvaccinated patientsVaccination statusHigh riskTreatment effectivenessHigh-risk individualsAllocation strategyPopulation-level strategiesWillingnessFurther priorityDrug costsSensitivity analysisCostRitonavir treatmentUnvaccinated personsVaccinated adultsPatient populationClinical trialsLower riskEstimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study
Savinkina A, Bilinski A, Fitzpatrick M, Paltiel AD, Rizvi Z, Salomon J, Thornhill T, Gonsalves G. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study. BMJ Open 2022, 12: e061752. PMID: 36100306, PMCID: PMC9471205, DOI: 10.1136/bmjopen-2022-061752.Peer-Reviewed Original ResearchConceptsLow-income countriesIncome countriesDeath avertedHigh-income nationsStatistical lifeAvertable deathsIncome nationsCOVID-19 deathsReasonable investmentHigh costKey inputCountriesParameter estimatesAvertedCostSensitivity analysisUniversal vaccinationGlobal vaccinationMRNA COVID-19 vaccinationNationsInvestmentPrimary vaccine seriesLow vaccine effectivenessCOVID-19 vaccinationPublic data
2021
Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic
Yaesoubi R, Havumaki J, Chitwood MH, Menzies NA, Gonsalves G, Salomon JA, Paltiel AD, Cohen T. Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic. Medical Decision Making 2021, 41: 386-392. PMID: 33504258, PMCID: PMC8084913, DOI: 10.1177/0272989x21990371.Peer-Reviewed Original ResearchConceptsAdaptive policiesClear decision rulesSocial costsEconomic costsPolicy makersPhysical distancing policiesDecision toolPolicyPhysical distancing interventionsDistancing policiesModel-based experimentsDecision rulesReal-time surveillance dataCostCOVID-19 pandemicMakersShorter overall durationMore complex modelsHealth benefitsComplex modelsPandemicCurrent pandemicCOVID-19BenefitsRules
2020
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2020, 172: 583-590. PMID: 32150602, PMCID: PMC7217721, DOI: 10.7326/m19-3478.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioCost-effectiveness analysisFair priceCost-effectiveness ratioBase-case analysisJustifiable priceSocietal willingnessComparative pricingHealth care sectorPricesTime horizonEnd-stage renal diseaseCases of ESRDQALYDemand PrEPCare sectorEconomic savingsHIV preexposure prophylaxisSensitivity analysisCostPreexposure prophylaxisLife effectsHorizonPricingDiscount
2013
Dengue dynamics and vaccine cost-effectiveness in Brazil
Durham DP, Mbah M, Medlock J, Luz PM, Meyers LA, Paltiel AD, Galvani AP. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine 2013, 31: 3957-3961. PMID: 23791696, PMCID: PMC3755607, DOI: 10.1016/j.vaccine.2013.06.036.Peer-Reviewed Original ResearchConceptsVaccination costsDengue vaccine trialsVaccine efficacyTotal vaccination costDengue vaccinationCost-effectiveness analysisPotential vaccination policiesVaccine trialsPay thresholdsVaccine efficacy scenariosOptimal allocationLow vaccine efficacyLatest clinical trialsOptimistic scenarioTrial estimatesVaccination coverageEfficacy scenariosClinical trialsAvailable dosesVaccination policyFurther trialsVaccination modelHerd immunityVaccinationCost
2003
Economic Costs of Influenza-Related Work Absenteeism
Akazawa M, Sindelar JL, Paltiel AD. Economic Costs of Influenza-Related Work Absenteeism. Value In Health 2003, 6: 107-115. PMID: 12641861, DOI: 10.1046/j.1524-4733.2003.00209.x.Peer-Reviewed Original ResearchConceptsNet benefitEconomic costsMedical Expenditure Panel Survey Household ComponentMean productivity costsAverage work lossDollar termsUS dollarsEmployment dataProductivity impactEconomic attractivenessNumber of workdaysWorking-age peopleHousehold ComponentProductivity costsWorker productivityWorker absenteeismEmployment factorsSimple frameworkInfluenza-like illnessDecision analysisReduced absenteeismCostBaseline analysisInfluenza vaccinationTerms of absence
1998
A Monte Carlo Simulation of Advanced HIV Disease
Paltiel AD, Scharfstein JA, Seage GR, Losina E, Goldie SJ, Weinstein MC, Craven DE, Freedberg KA. A Monte Carlo Simulation of Advanced HIV Disease. Medical Decision Making 1998, 18: s93-s105. PMID: 9566470, DOI: 10.1177/0272989x98018002s11.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioMonte Carlo simulation frameworkDecision makersCost-effectiveness ratioQuality-adjusted monthsPrice assumptionsNet costLife yearsData estimatesCost-effective usePatient care resourcesState transition modelCare resourcesMakersAdvanced HIV diseaseSensitivity analysisLate-stage diseaseBaseline resultsAlternative interventionsQuality of lifeTreatment of AIDSCostCMV prophylaxisGanciclovir prophylaxisResource Allocation and the Funding of HIV Prevention
Paltiel A, Stinnett A. Resource Allocation and the Funding of HIV Prevention. Aids Prevention And Mental Health 1998, 135-152. DOI: 10.1007/978-1-4899-1878-9_10.Peer-Reviewed Original ResearchDecision makersTragic epidemicSociety's resourcesPriority settingConsequences of interventionsResource allocationCollective safetyHIV preventionMakersAttractive programsLimited resourcesResourcesSocial debateAllocationFundingTangled webCostBackdropPreventionDebateObligationsConstant struggleLimited information